A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression * Availability of tissue for analysis * ECOG Performance Status 0 or 1 * Adequate organ function as defined in the protocol. * Must be at least 18 years old and able and willing to sign a written informed consent document Exclusion Criteria: * Poor venous access requiring an indwelling catheter for study drug administration * Women who are pregnant or lactating * Ventricular ejection fraction \< or = to 55% at baseline * Any uncontrolled intercurrent illness